Initial Studies with ¹¹C-Vorozole PET Detect Overexpression of Intratumoral Aromatase in Breast Cancer.

ABSTRACT: Aromatase inhibitors are the mainstay of hormonal therapy in estrogen receptor-positive breast cancer, although the response rate is just over 50% and in vitro studies suggest that only two thirds of postmenopausal breast tumors overexpress aromatase. The goal of the present study was to validate and optimize PET with ¹¹C-vorozole for measuring aromatase expression in postmenopausal breast cancer in vivo. Methods: Ten newly diagnosed postmenopausal women with biopsy-confirmed breast cancer were administered ¹¹C-vorozole intravenously, and PET emission data were collected between 40 and 90 min after injection. Tracer injection and scanning were repeated 2 h after ingestion of 2.5 mg of letrozole. Mean and maximal SUVs and ratios to nontumor tissue in the contral

SUBMITTER: Biegon A 

PROVIDER: S-EPMC7262229 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature